Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T + ASCT in R/R T-cell Lymphoma
NCT07117305Phase 2Not yet recruiting
- Sponsor
- Zhengzhou University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
A Phase 2 trial of CD7 CAR-T cells injection in T-cell lymphoma, sponsored by Zhengzhou University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
CD7 CAR-T cells injection
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT07117305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117305.